Table 1.
Characteristics of enrolled patients.
| Features | n (%) |
|---|---|
| Total | 134 |
| Severe thrombocytopenia | 12 (9.0%) |
| Age | |
| <3 yr | 83 (61.9%) |
| 3–18 yr | 51 (38.1%) |
| Sex (female) | 41 (30.6%) |
| Treatment duration | |
| 5–7 d | 42 (31.3%) |
| 8–14 d | 66 (49.3%) |
| >14 d | 26 (19.4%) |
| Comorbidities | |
| Respiratory tract diseases | 40 (29.9%) |
| Heart diseases | 31 (23.1%) |
| Central nervous system diseases | 21 (15.7%) |
| Autoimmune diseases | 8 (6.0%) |
| Digestive system disease | 13 (9.7%) |
| Urinary system disease | 2 (1.5%) |
| Musculoskeletal system disease | 6 (4.5%) |
| Endocrine system disease | 4 (3.0%) |
| Skin and soft-tissue disease | 6 (4.5%) |
| Inherited metabolic disorders | 3 (2.2%) |
| Solid organ malignancy | 9 (6.7%) |
| Sepsis | 16 (12.0%) |
| Isolated microorganisms | |
| Enterococci | 10 (7.5%) |
| MRCoNS | 17 (12.7%) |
| MSCoNS | 4 (3.0%) |
| Streptococcus spp. | 15 (11.2%) |
| MRSA | 5 (3.7%) |
| MSSA | 4 (3.0%) |
| Concomitant drugs | |
| Carbapenem | 63 (47.0%) |
| Piperacillin-tazobactam | 11 (8.2%) |
| SMZ-TMP | 5 (3.7%) |
| Valproic acid | 10 (7.5%) |
| Heparin/LMWH | 73 (54.5%) |
| ICU admission | 57 (42.5%) |
| In-hospital mortality | 7 (5.2%) |
ICU = intensive care unit, LMWH = low-molecular-weight heparin, MRCoNS = methicillin-resistant coagulase-negative Staphylococcus, MRSA = methicillin-resistant Staphylococcus aureus, MSCoNS = methicillin- sensitive coagulase-negative Staphylococcus, MSSA = methicillin-sensitive Staphylococcus aureus, SMZ-TMP = sulfamethoxazole-trimethoprim.